McKesson Corporation vs Zillow Group Inc Class A — how do they compare? McKesson Corporation trades at $938.84 (market cap $108.46B), while Zillow Group Inc Class A trades at $29.87 (market cap $6.59B). The key difference: McKesson Corporation is far larger — about 16.5× Zillow Group Inc Class A's market cap, and McKesson Corporation pays a 0.4% dividend while Zillow Group Inc Class A pays none. Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Zillow Group Inc Class A for 86 Days on average.
| MCK | ZG | |
|---|---|---|
Market Cap | $108.46B | $6.59B |
Volume | 712,607 | 1,361,381 |
Sector | Health | Media |
52-Week High | $995.69 | $74.58 |
52-Week Low | $725.17 | $27.70 |
Typical Hold Time | 74 Days | 86 Days |
Enterprise Value | $115.00B | $6.47B |
Dividend Yield | 0.4% | — |
Signals from Pluang's Aura AI — not financial advice
McKesson Corporation (MCK) trades at $930.25, up 2.19% with strong technical momentum and bullish analyst sentiment. The stock shows consistent earnings beats with Q2 2026 EPS of $9.93 exceeding expectations of $9.56. Recent news highlights the extension of McKesson's pharmaceutical distribution agreement with CVS Health through 2032, reinforcing long-term revenue visibility. Revenue growth remains robust, climbing from $264.0B in 2022 to $359.1B in 2025, though net margins are thin at 1.12%.
McKesson presents a favorable risk-reward profile with 81% analyst buy ratings and a $956.43 consensus price target offering 2.8% upside. Key risks include margin pressure from drug pricing dynamics and policy uncertainty. The company's strong cash flow generation ($6.1B operating cash flow in 2025) and strategic focus on oncology and specialty distribution support continued growth, though investors should monitor debt levels and competitive pressures in healthcare distribution.
Zillow Group (ZG) trades at $29.90, up 6.9% in the last session, showing strong momentum despite mixed technical signals. The company has demonstrated improving fundamentals with revenue growth to $2.58 billion in 2025 and a return to profitability with net income of $23 million. Recent earnings beats in Q1 and Q2 2026 suggest operational improvement, though cash flow trends remain volatile with negative net cash flow of $312 million in 2025.
The stock presents a compelling turnaround story with improving profitability and strong analyst price targets averaging $48.87, offering significant upside potential. However, investors face risks from the volatile housing market, high P/E ratio of 130, and ongoing competitive pressures in the real estate technology sector that could challenge future growth.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →